934 related articles for article (PubMed ID: 27966046)
21. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
22. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
23. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
[TBL] [Abstract][Full Text] [Related]
24. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
25. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
26. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected].
Al-Qahtani KH; Al Asiri M; Tunio MA; Aljohani NJ; Bayoumi Y; Fatani H; AlHadab A
J Otolaryngol Head Neck Surg; 2015 Dec; 44():51. PubMed ID: 26621255
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
[TBL] [Abstract][Full Text] [Related]
29. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
[TBL] [Abstract][Full Text] [Related]
30. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
31. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
33. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
[TBL] [Abstract][Full Text] [Related]
34. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
[TBL] [Abstract][Full Text] [Related]
36. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Pathologically Positive Lymph Nodes in the Clinically Negative Neck: An Analysis of 39,301 Patients with Papillary Thyroid Cancer.
Ruel E; Thomas S; Perkins JM; Roman SA; Sosa JA
Ann Surg Oncol; 2017 Jul; 24(7):1935-1942. PubMed ID: 28127652
[TBL] [Abstract][Full Text] [Related]
38. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
Schvartz C; Bonnetain F; Dabakuyo S; Gauthier M; Cueff A; Fieffé S; Pochart JM; Cochet I; Crevisy E; Dalac A; Papathanassiou D; Toubeau M
J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
[TBL] [Abstract][Full Text] [Related]
39. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.
Zhao Y; Mu Z; Liang D; Zhang T; Zhang X; Sun D; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2024; 15():1354426. PubMed ID: 38721144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
